BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Morria Biopharmaceuticals Plc 

53 Davies street

Mayfair  London  W1K5JH  United Kingdom
Phone: 44-0-207-152-6341 Fax: 44-0-207-152-6342


SEARCH JOBS


Industry
Biotechnology






 Company News
Morria Biopharmaceuticals Plc Names Dr. Gur Roshwalb as CEO 3/5/2013 7:52:33 AM    More...
Morria Biopharmaceuticals Plc Announces Quotation for Trading on the OTC Bulletin Board 2/19/2013 9:04:23 AM    More...
Morria Biopharmaceuticals Plc Announces Full Time Appointment of Alan Harris, M.D., Ph.D., as Chief Medical Officer 1/23/2013 9:14:08 AM    More...
Morria Biopharmaceuticals Plc Appoints Charles Serhan Ph.D. to Scientific Advisory Board 7/18/2012 8:39:30 AM    More...
Morria Biopharmaceuticals Plc Appoints Alan Harris, M.D., Ph.D., as Chief Medical Officer 7/2/2012 10:26:13 AM    More...
Morria Biopharmaceuticals Plc Selects SCYNEXIS, Inc. to Support CMC Activities for MRX-4, a Novel Anti-Inflammatory Drug for Allergic Rhinitis 2/16/2012 8:41:39 AM    More...
Morria Biopharmaceuticals Plc Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress 6/15/2010 7:12:26 AM    More...
Promising Safety, Tolerability and Efficacy Results from Morria Biopharmaceuticals Plc' MRX-4 Phase II Study in Allergic Rhinitis to be Presented at the upcoming EAACI Congress 6/3/2010 9:46:29 AM    More...
Morria Biopharmaceuticals Plc Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug 4/21/2010 9:21:55 AM    More...
Morria Biopharmaceuticals Plc Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug 8/25/2009 9:57:43 AM    More...
123

//-->